1. Neurodegenerative Disease Treatment Drug PBT2 Breaks Intrinsic Polymyxin Resistance in Gram-Positive Bacteria
- Author
-
De Oliveira, DMP, Keller, B, Hayes, AJ, Ong, C-LY, Harbison-Price, N, El-Deeb, IM, Li, G, Keller, N, Bohlmann, L, Brouwer, S, Turner, AG, Cork, AJ, Jones, TR, Paterson, DL, McEwan, AG, Davies, MR, McDevitt, CA, von Itzstein, M, Walker, MJ, De Oliveira, DMP, Keller, B, Hayes, AJ, Ong, C-LY, Harbison-Price, N, El-Deeb, IM, Li, G, Keller, N, Bohlmann, L, Brouwer, S, Turner, AG, Cork, AJ, Jones, TR, Paterson, DL, McEwan, AG, Davies, MR, McDevitt, CA, von Itzstein, M, and Walker, MJ
- Abstract
Gram-positive bacteria do not produce lipopolysaccharide as a cell wall component. As such, the polymyxin class of antibiotics, which exert bactericidal activity against Gram-negative pathogens, are ineffective against Gram-positive bacteria. The safe-for-human-use hydroxyquinoline analog ionophore PBT2 has been previously shown to break polymyxin resistance in Gram-negative bacteria, independent of the lipopolysaccharide modification pathways that confer polymyxin resistance. Here, in combination with zinc, PBT2 was shown to break intrinsic polymyxin resistance in Streptococcus pyogenes (Group A Streptococcus; GAS), Staphylococcus aureus (including methicillin-resistant S. aureus), and vancomycin-resistant Enterococcus faecium. Using the globally disseminated M1T1 GAS strain 5448 as a proof of principle model, colistin in the presence of PBT2 + zinc was shown to be bactericidal in activity. Any resistance that did arise imposed a substantial fitness cost. PBT2 + zinc dysregulated GAS metal ion homeostasis, notably decreasing the cellular manganese content. Using a murine model of wound infection, PBT2 in combination with zinc and colistin proved an efficacious treatment against streptococcal skin infection. These findings provide a foundation from which to investigate the utility of PBT2 and next-generation polymyxin antibiotics for the treatment of Gram-positive bacterial infections.
- Published
- 2022